HOME › DRUGS › APREPITANT
ACTIVE SUBSTANCE / INN

APREPITANT

Brand name(s): CINVANTI, APONVIE, EMEND, Emend, APREPITANT
FDA LISTED
EMA LISTED
PRESCRIPTION
DISCONTINUED
AUTHORISED
Vomiting;Postoperative Nausea and Vomiting;Cancer
NDA207865
ACTIVE SUBSTANCE
Aprepitant
REGULATORS
FDA · EMA
SPONSORS / MAH
MSD, Merck Sharp & Dohme B.V., HERON THERAPS INC
TOTAL APPLICATIONS
7
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
EMENDNDA207865MSD MERCK COPrescription
CINVANTINDA209296HERON THERAPS INCPrescription
EMENDNDA021549MSDDiscontinued
APONVIENDA216457HERON THERAPS INCPrescription
APREPITANTANDA216976MYLAN PHARMACEUTICALS INCNone (Tentative Approval)
APREPITANTANDA207777GLENMARK SPECLTPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
EmendMerck Sharp & Dohme B.V.Authorised11/11/2003Vomiting;Postoperative Nausea and Vomiting;Cancer

FULL INTELLIGENCE ON APREPITANT

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →